Gepride M2 Tablet PR contains a combination of Glimepiride 2 mg and Metformin 500 mg, formulated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, enhances pancreatic beta-cell insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity. The combination provides a complementary mechanism of action, facilitating better blood glucose regulation in patients inadequately controlled by diet and exercise alone. Gepride M2 Tablet PR is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. The extended-release formulation allows for sustained plasma drug levels, promoting improved patient compliance through reduced dosing frequency and minimizing gastrointestinal side effects commonly associated with metformin. Caution is advised in patients with renal impairment, hepatic dysfunction, or conditions predisposing to hypoxia, as these may increase the risk of lactic acidosis. Regular monitoring of blood glucose, renal function, and liver enzymes is recommended during therapy. Patients should be counseled on recognizing symptoms of hypoglycemia and maintaining adherence to lifestyle modifications. Gepride M2 Tablet PR should be used under medical supervision with individualized dosing to achieve optimal therapeutic outcomes.